
Melanie P. Matheu, PhD
Co-founder & CSO
Dr. Matheu holds a PhD in Physiology and Biophysics with a special emphasis in Immunology. Dr. Matheu is the founder of Prellis Biologics, Inc where the high-resolution laser printing of 3D tissues that Lyric uses for it's bioreactors was developed. During her tenure in academia, Dr. Matheu was awarded over $1M in grant funding and enabled over $30M in collaborative grant awards. In 2016 Dr. Matheu left academia and shortly after founded Prellis Biologics, Inc. Dr. Matheu is the technical inventor of Prellis Biologics’ novel laser-based printing system which is up to 10,000-fold faster than other laser-based bioprinting systems at the same resolution.
Melanie led Prellis Biologics as the CEO for six and a half years raising over $65M at over a $120M valuation. Dr. Matheu still serves as a Board Member and CTO of Prellis Biologics, Inc. and is spearheading the spin-out of novel manufacturing technology with the establishment of Lyric Biosciences, Inc. where she will bring her scientific expertise as CSO.